The price of Intuitive Surgical Inc. (NASDAQ:ISRG) shares last traded on Wall Street fell -3.16% to $336.66.
Based on available information, 28 analysts follow Intuitive Surgical Inc. (NASDAQ:ISRG). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $400.00 and a low of $315.00, we find $373.00. Given the previous closing price of $347.66, this indicates a potential upside of 7.29 percent. ISRG stock price is now 4.28% away from the 50-day moving average and 25.01% away from the 200-day moving average. The market capitalization of the company currently stands at $121.82B.
Among analysts, 10 rate the stock a hold while 11 rate it a buy. Brokers who have rated the stock have averaged $365.67 as their price target over the next twelve months.
With the price target of $377, Robert W. Baird recently initiated with Outperform rating for Intuitive Surgical Inc. (NASDAQ: ISRG).
In other news, MOHR MARSHALL, Executive VP Global Business S sold 11,250 shares of the company’s stock on Jun 14. The stock was sold for $3,656,250 at an average price of $325.00. Upon completion of the transaction, the Executive VP Global Business S now directly owns 24,136 shares in the company, valued at $8.13 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 14, EVP & Chief Product Officer DeSantis Robert sold 2,443 shares of the business’s stock. A total of $793,975 was realized by selling the stock at an average price of $325.00. This leaves the insider owning 7,259 shares of the company worth $2.44 million. Insiders disposed of 419,035 shares of company stock worth roughly $141.07 million over the past 1 year. A total of 0.51% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ISRG stock. A new stake in Intuitive Surgical Inc. shares was purchased by RENAISSANCE TECHNOLOGIES LLC during the first quarter worth $138,815,000. TCW GROUP INC invested $86,216,000 in shares of ISRG during the first quarter. In the first quarter, VOLORIDGE INVESTMENT MANAGEMENT, LLC acquired a new stake in Intuitive Surgical Inc. valued at approximately $75,662,000. OFI INVEST ASSET MANAGEMENT acquired a new stake in ISRG for approximately $69,751,000. SOFINNOVA INVESTMENTS, INC. purchased a new stake in ISRG valued at around $50,361,000 in the second quarter. In total, there are 2,044 active investors with 86.60% ownership of the company’s stock.
A candlestick chart of Intuitive Surgical Inc. (NASDAQ: ISRG) showed a price of $335.91 on Friday morning. During the past 12 months, Intuitive Surgical Inc. has had a low of $180.07 and a high of $358.07. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.30, and a quick ratio of 4.50. According to the stock market information, the enterprise value for the company is $113.82B, which is based on a 84.48 price-to-earnings ratio, a 5.37 price-to-earnings-growth ratio, and a beta of 1.32. The fifty day moving average price for ISRG is $323.54 and a two-hundred day moving average price translates $270.01 for the stock.
The latest earnings results from Intuitive Surgical Inc. (NASDAQ: ISRG) was released for Mar, 2023. According to the Medical Instruments & Supplies Company, earnings per share came in at $1.42, beating analysts’ expectations of $1.33 by 0.09. This compares to $1.01 EPS in the same period last year. The net profit margin was 19.80% and return on equity was 11.50% for ISRG. The company reported revenue of $1.7 billion for the quarter, compared to $1.49 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.01 percent. For the current quarter, analysts expect ISRG to generate $1.78B in revenue.
Intuitive Surgical Inc.(ISRG) Company Profile
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
